Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HQP 8361

Next Previous
Search
Drug Profile

HQP 8361

Alternative Names: HQP-8361; MK-8033

Latest Information Update: 17 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme Corp.
  • Developer Ascentage Pharma; Merck Sharp & Dohme Corp.
  • Class 3-ring heterocyclic compounds; Antineoplastics; Cyclopentanes; Pyrazoles; Pyridines; Small molecules; Sulfonamides
  • Mechanism of Action Proto-oncogene protein c-met inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Cancer

Most Recent Events

  • 28 Sep 2022 Phase-II clinical trials in Solid tumours (Late-stage disease) in China (PO), prior to September 2022 (Ascentage Pharma, September 2022)
  • 28 Sep 2022 HQP 8361 is still in phase I trials for Solid tumours (Late-stage disease) in (China) (PO, Capsule) (Ascentage pipeline)
  • 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top